EP2921482A2 — Labeled inhibitors of prostate-specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
Assigned to Johns Hopkins University · Expires 2015-09-23 · 11y expired
What this patent protects
The present invention provides radiolabeled compounds of formulae (VII) and (VIII) comprising a urea derivative, a linker, a metal chelating group, and a radiolabeled or isotopically labelled metal, pharmaceutical compositions comprising such radiolabeled compounds and methods of…
USPTO Abstract
The present invention provides radiolabeled compounds of formulae (VII) and (VIII) comprising a urea derivative, a linker, a metal chelating group, and a radiolabeled or isotopically labelled metal, pharmaceutical compositions comprising such radiolabeled compounds and methods of detecting PSMA expressing tumors. The compounds of the invention are useful for providing diagnosis of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.